

## Cannabidiol in the Control of Refractory Seizures.

The following references are useful in evaluating the role of cannabidiol in the control of refractory seizures.<sup>(1-10)</sup>

1. Cilio MR, Thiele EA, Devinsky O. The case for assessing cannabidiol in epilepsy. *Epilepsia*. 2014;55(6):787-90. Epub 2014/05/24. doi: 10.1111/epi.12635. PubMed PMID: 24854434.
2. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. *Epilepsia*. 2014;55(6):791-802. Epub 2014/05/24. doi: 10.1111/epi.12631. PubMed PMID: 24854329.
3. Cannabidiol as a potential treatment for psychosis *European Neuropsychopharmacology* Volume 24, Issue 1, January 2014, Pages 51–64
4. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. *Pharmacology*. 1980;21(3):175-85. Epub 1980/01/01. PubMed PMID: 7413719.
5. Gloss D, Vickrey B. Cannabinoids for epilepsy. *The Cochrane database of systematic reviews*. 2014;3:CD009270. Epub 2014/03/07. doi: 10.1002/14651858.CD009270.pub3. PubMed PMID: 24595491.
6. Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. *Seizure : the journal of the British Epilepsy Association*. 2012;21(5):344-52. Epub 2012/04/24. doi: 10.1016/j.seizure.2012.03.001. PubMed PMID: 22520455.
7. Maa E, Figi P. The case for medical marijuana in epilepsy. *Epilepsia*. 2014;55(6):783-6. Epub 2014/05/24. doi: 10.1111/epi.12610. PubMed PMID: 24854149.
8. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. *Epilepsy & behavior : E&B*. 2013;29(3):574-7. Epub 2013/11/19. doi: 10.1016/j.yebeh.2013.08.037. PubMed PMID: 24237632.
9. Robson PJ. Therapeutic potential of cannabinoid medicines. *Drug testing and analysis*. 2014;6(1-2):24-30. Epub 2013/09/06. doi: 10.1002/dta.1529. PubMed PMID: 24006213.
10. Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. *Pharmaceuticals (Basel, Switzerland)*. 2012;5(5):529-52. Epub 2012/01/01. doi: 10.3390/ph5050529. PubMed PMID: 24281562; PubMed Central PMCID: PMC3763649.
11. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia *Citation: Translational Psychiatry (2012) 2, e94; doi:10.1038/tp.2012.15*
12. Fernandez-Ruiz J, Sagredo O, Pazos MR, Garcia C, Pertwee R, Mechoulam R, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? *British journal of clinical pharmacology*. 2013;75(2):323-33. Epub 2012/05/26. doi: 10.1111/j.1365-2125.2012.04341.x. PubMed PMID: 22625422; PubMed Central PMCID: PMC3579248.
13. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. *Drugs R D*. 2003;4(5):306-9
14. <http://www.gwpharm.com/Epidiolex.aspx>

## **Cannabidiol in the Control of Refractory Seizures.**

<http://www.gwpharm.com/Rationale%20and%20Preclinical.aspx>

<http://www.gwpharm.com/Clinical%20Use.aspx>

Ronald A. Herman, Ph.D., R.Ph.

Clinical Pharmacy Specialist – IRB Reviews

Drug Information Center | Dept. of Pharmaceutical Care

Univ. of Iowa Health Care | 200 Hawkins Dr. | C108 GH

Iowa City, IA 52242

PH 319.356.1467 | Cell 319.530.9867

[rhherman@healthcare.uiowa.edu](mailto:rhherman@healthcare.uiowa.edu)

Charuta Joshi MBBS

Clinical Professor in pediatric Neurology

Director of Pediatric Epilepsy

200 Hawkins Drive , UIHC

Phone 319-356-1851